United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,258 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $122.08, for a total transaction of $153,576.64. Following the sale, the chief executive officer now owns 2,327 shares in the company, valued at approximately $284,080.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Corporation (NASDAQ:UTHR) opened at 120.79 on Friday. The company has a market cap of $5.25 billion, a P/E ratio of 14.01 and a beta of 1.52. The company’s 50-day moving average is $128.92 and its 200-day moving average is $129.77. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $4.42 EPS. On average, equities research analysts expect that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Martine A. Rothblatt Sells 1,258 Shares of United Therapeutics Corporation (UTHR) Stock” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/17/martine-a-rothblatt-sells-1258-shares-of-united-therapeutics-corporation-uthr-stock.html.

A number of equities research analysts have recently commented on the stock. BidaskClub cut shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Finally, Jefferies Group LLC reiterated a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a report on Friday, July 14th. Six research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $134.50.

A number of large investors have recently added to or reduced their stakes in the business. HPM Partners LLC grew its position in United Therapeutics Corporation by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 15 shares during the last quarter. First Allied Advisory Services Inc. grew its position in United Therapeutics Corporation by 0.4% during the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after purchasing an additional 19 shares during the last quarter. Nomura Asset Management Co. Ltd. grew its position in United Therapeutics Corporation by 0.3% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock worth $1,712,000 after purchasing an additional 40 shares during the last quarter. Fisher Asset Management LLC grew its position in United Therapeutics Corporation by 1.4% during the 2nd quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 45 shares during the last quarter. Finally, Argent Capital Management LLC grew its position in United Therapeutics Corporation by 2.4% during the 1st quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock worth $343,000 after purchasing an additional 60 shares during the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.